7 completed. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 1 | 1 | Completed 1 |
Follow Bone scan: new trials by email Literature Review of Bone scan trials Research Report on Bone scan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) M7824, N-803, MVA-BN-Brachyury - Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 59 | 2018-05-01 | 2025-09-30 |
| Combination Immunotherapy in Biochemically Recurrent Prostate Cancer Antigen direct immunotherapy: PROSTVAC-V, Antigen direct immunotherapy: PROSTVAC-F, MSB0011359C (M7824) - Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2018-03-20 | 2025-06-19 |
| Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 152 | 2016-07-25 | 2025-01-13 |
| Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide Enzalutamide, 11C or 18F-Choline PET/CT, Whole body MRI - Prostate Cancer Metastatic | Phase 2 | Completed | The European Uro-Oncology Group | 66 | 2015-07-01 | 2022-04-14 |
| A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer Blood Tests, CT scan, FACBC PET/MRI in a subset of participants - Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Completed | Massachusetts General Hospital | 22 | 2015-04-01 | 2022-09-29 |
| PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide Enzalutamide, 18-FDG PET/CT, Whole body MRI - Prostate Cancer Metastatic | Phase 2 | Completed | The European Uro-Oncology Group | 66 | 2015-02-01 | 2022-04-14 |
| Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases Bone scan, 99mTc-methyl diphosphonate, Positron Emission Tomography (PET) scan - Cancer | Phase 2 | Completed | Stanford University | 114 | 2006-01-01 | 2023-12-12 |
Prostatic Neoplasms (3) · Carcinoma, Renal Cell (1) · Neoplasms (1)
National Cancer Institute (NCI) (3) · The European Uro-Oncology Group (2) · Massachusetts General Hospital (1) · Stanford University (1)
United States (5) · Netherlands (2) · Canada (1)
Susanne Osanto, MD PhD (2) · Andrei Iagaru, MD (1) · James L Gulley, M.D. (1) · Philip J Saylor, MD (1) · Ravi A Madan, M.D. (1) · Sumanta K Pal (1)
PMID 23455520, PMID 26405167, PMID 26956325, PMID 30227893, PMID 31236756, PMID 33592176, PMID 33602696, PMID 37146227, PMID 39255440, PMID 42498485
U10CA180888 (1)